Cancer Genetics and Epigenetics 2017, Vol.5, No.1, 1
-
5
5
Petridis C., Shinomiya I., Kohut K., Gorman P., Caneppele M., Shah V., Troy M., Pinder S.E., Hanby A., Tomlinson I., Trembath R.C., Roylance R., Simpson
M.A., and Sawyer E.J., 2014, Germline CDH1 mutations in bilateral lobular carcinoma in suit, British Journal of Cancer, 110(4): 1053-1057
PMid:24366306 PMCid:PMC3929874
Rakha E.A., van Deurzen C.H., Paish E.C., Macmillan R.D., Ellis I.O., and Lee A.H., 2013, Pleomorphic lobular carcinoma of the breast: is it a prognostically
significant pathological subtype independent of histological grade? Modern Pathology an Official Journal of the United States and Canadian Academy of
Pathology Inc, 6(2): 496-501
PMid:23238630
Reed A.E.M., Kutasovic J.R., Lakhani S.R., and Simpson P.T., 2015, Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics, Breast
Cancer Research, 17(1): 1-11
PMid:25849106 PMCid:PMC4310190
Sikora M.J., Cooper K.L., Bahreini A., Luthra S., Wang G.Y., Chandran U.R., Davidson N.E., Dabbs D.J., Welm A.L., and Oesterreich S., 2014, Invasive
lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response, Cancer Research,
74(5): 1463-1474
PMid:24425047 PMCid:PMC3955299
Sinn H.P., Helmchen B., Heil J., and Aulmann S., 2014, Lobular neoplasms and invasive lobular breast cancer, Der Pathologe, 35(1): 45-53
PMid:24435155
Sonnenblick A., Francis P.A., Azim H.A.J., de Azambuja E., Nordenskjöld B., Gutiérez J., Quinaux E., Mastropasqua M.G., Ameye L., Anderson M., Lluch A.,
Gnantl M., Goldhirsch A., Leo A.D., Barnadas A., Cortes-Funes H., Piccart M., and Crown J., 2015, Final 10-year results of the Breast International Group
2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer, European
Journal of Cancer, 51(12): 1481-1489
PMid:26074397
Swain S.M., Im Y.H., Im S.A., Chan V., Miles D., Knott A., Clark E., Ross G., and Baselga J., 2014, Safety profile of pertuzumab with trastuzumab and
docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial
CLEOPA-TRA, Oncologist, 19(7): 693-701
PMid:24869931 PMCid:PMC4077449
